April 2015 | The Journal of Targeted Therapies in Cancer

Ibrutinib in the Management of B-cell Malignancies

May 22, 2015

Clinical Articles

While ibrutinib is a relatively new option in the treatment of B-cell NHL, it has convincing antitumor activity as a single agent in a wide variety of B-cell lymphoma subtypes and is a viable therapeutic option for patients.